What is Ultragenyx Pharmaceutical's AOCI?

Ultragenyx Pharmaceutical (RARE) reported AOCI of $0 in Q1 2026.

How has Ultragenyx Pharmaceutical's AOCI changed year-over-year?

Ultragenyx Pharmaceutical's AOCI increased by 100.0% year-over-year, from -$341K to $0.

What is the long-term trend for Ultragenyx Pharmaceutical's AOCI?

Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's AOCI has grown at a 7.7% compound annual growth rate (CAGR), from $689K to $1M.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Ultragenyx Pharmaceutical RARE AOCI

AOCI at other companies

Eli LillyLLY

-$2.83B+24.9%

AmgenAMGN

-$190M+17.7%

Ionis PharmaceuticalsIONS

-$31.02M-7.2%

Arrowhead ResearchARWR

$742K-83.1%

CRISPR TherapeuticsCRSP

-$1.94M-147%

ModernaMRNA

$25M+150%

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's AOCI?: Ultragenyx Pharmaceutical (RARE) reported AOCI of $0 in Q1 2026.
How has Ultragenyx Pharmaceutical's AOCI changed year-over-year?: Ultragenyx Pharmaceutical's AOCI increased by 100.0% year-over-year, from -$341K to $0.
What is the long-term trend for Ultragenyx Pharmaceutical's AOCI?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's AOCI has grown at a 7.7% compound annual growth rate (CAGR), from $689K to $1M.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.